New therapeutic could defend against SARS-CoV-2 and future viruses

Data from preclinical studies of a newly developed antibody shows it to be more effective than monoclonal antibodies in clinical trials, while providing defense against a broader range of threats. As new ground is being broken in vaccine development and the prospects for several successful vaccines against SARS-CoV-2 look promising, the importance of finding a successful treatment for this coronavirus and those like it does not diminish. New in vivo and in vitro data from a novel therapeutic for SARS-CoV-2, currently in preclinical trials, have been released. The data show the therapeutic, an antibody labeled ADG2, to be as (or...